PNC Financial Services Group Inc. Purchases New Position in Inhibrx, Inc. (NASDAQ:INBX)

PNC Financial Services Group Inc. purchased a new stake in Inhibrx, Inc. (NASDAQ:INBX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,798 shares of the company’s stock, valued at approximately $28,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Inhibrx during the fourth quarter valued at $47,000. New York State Common Retirement Fund bought a new position in shares of Inhibrx during the fourth quarter worth $53,000. Exchange Traded Concepts LLC bought a new position in Inhibrx during the fourth quarter worth about $148,000. Rhumbline Advisers acquired a new position in shares of Inhibrx in the 4th quarter valued at approximately $228,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Inhibrx in the fourth quarter valued at approximately $348,000. 82.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Stock Up 0.6 %

NASDAQ:INBX opened at $14.32 on Friday. The firm’s 50-day simple moving average is $13.35 and its 200 day simple moving average is $14.61. Inhibrx, Inc. has a 52 week low of $10.80 and a 52 week high of $35.42.

Inhibrx (NASDAQ:INBX) last announced its quarterly earnings data on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The business had revenue of $0.10 million for the quarter. Research analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.